Background
Down syndrome is by far the most common and best known chromosomal disorder in humans and the most common cause of intellectual disability.[1, 2, 3, 4, 5] It is characterized by mental retardation, dysmorphic facial features, and other distinctive phenotypic traits. Down syndrome is primarily caused by trisomy of chromosome 21; this is the most common trisomy among live births. The term mongolism was once commonly used but is now considered obsolete.[6, 7, 8]
Like most diseases associated with chromosomal abnormalities, trisomy 21 gives rise to multiple systemic complications as part of the clinical syndrome. This chromosomal anomaly leads to both structural and functional defects in patients with Down syndrome. However, not all defects occur in each patient; there is a wide range of phenotypic variation.
Pathophysiology
The extra chromosome 21 affects almost every organ system and results in a wide spectrum of phenotypic consequences. These include life-threatening complications, clinically significant alteration of life course (eg, mental retardation), and dysmorphic physical features. Down syndrome decreases prenatal viability and increases prenatal and postnatal morbidity. Affected children have delays in physical growth, maturation, bone development, and dental eruption.
Two different hypotheses have been proposed to explain the mechanism of gene action in Down syndrome: developmental instability (ie, loss of chromosomal balance) and the so-called gene-dosage effect.[9] According to the gene-dosage effect hypothesis, the genes located on chromosome 21 have been overexpressed in cells and tissues of Down syndrome patients, and this contributes to the phenotypic abnormalities.[10]
The extra copy of the proximal part of 21q22.3 appears to result in the typical physical phenotype, which includes the following:
- Mental retardation - Most patients with Down syndrome have some degree of cognitive impairment, ranging from mild (intelligence quotient [IQ] 50-75) to severe impairment (IQ 20-35); patients show both motor and language delays during childhood
- Characteristic facial features
- Hand anomalies
- Congenital heart defects - Almost half of affected patients have congenital heart disease, including ventricular septal defect and atrioventricular canal defect
Molecular analysis reveals that the 21q22.1-q22.3 region, also known as the Down syndrome critical region (DSCR), appears to contain the gene or genes responsible for the congenital heart disease observed in Down syndrome. A new gene, DSCR1, identified in region 21q22.1-q22.2, is highly expressed in the brain and the heart and is a candidate for involvement in the pathogenesis of Down syndrome, particularly with regard to mental retardation and cardiac defects.
Abnormal physiologic functioning affects thyroid metabolism and intestinal malabsorption. Patients with trisomy 21 have an increased risk of obesity. Frequent infections are presumably due to impaired immune responses, and the incidence of autoimmunity, including hypothyroidism and rare Hashimoto thyroiditis, is increased.
Patients with Down syndrome have decreased buffering of physiologic reactions, resulting in hypersensitivity to pilocarpine and abnormal responses on sensory-evoked electroencephalographic (EEG) tracings. Children with leukemic Down syndrome also have hyperreactivity to methotrexate.
Decreased buffering of metabolic processes results in a predisposition to hyperuricemia and increased insulin resistance. Diabetes mellitus develops in many affected patients. Premature senescence causes cataracts and Alzheimer disease. Leukemoid reactions of infancy and an increased risk of acute leukemia indicate bone-marrow dysfunction.
Children with Down syndrome are predisposed to developing leukemia, particularly transient myeloproliferative disorder and acute megakaryocytic leukemia. Nearly all children with Down syndrome who develop these types of leukemia have mutations in the hematopoietic transcription factor gene, GATA1. Leukemia in children with Down syndrome requires at least 3 cooperating events: trisomy 21, a GATA1 mutation, and a third undefined genetic alteration.
Musculoskeletal manifestations in patients with Down syndrome include reduced height, atlanto-occipital and atlantoaxial hypermobility, and vertebral malformations of the cervical spine. These findings may lead to atlanto-occipital and cervical instability, as well as complications such as weakness and paralysis.
About 5% of patients with Down syndrome have gastrointestinal (GI) manifestations, including duodenal atresia, Hirschsprung disease, and celiac disease. Many patients with trisomy 21 have otorhinolaryngologic manifestations, including hearing loss and recurrent ear infections. About 60% of patients have ophthalmic manifestations.
The American College of Obstetricians and Gynecologists (ACOG) has published pertinent guidelines on screening for fetal chromosomal abnormalities.[11]
Etiology
Down syndrome is caused by the following 3 cytogenic variants:
- Trisomy 21
- Chromosomal translocation
- Mosaicism
In 94% of patients with Down syndrome, full trisomy 21 is the cause; mosaicism (2.4%) and translocations (3.3%) account for the remaining cases. Approximately 75% of the unbalanced translocations are de novo, and approximately 25% result from familial translocation.
A free trisomy 21 results from nondisjunction during meiosis in one of the parents. This occurrence is correlated with advanced maternal and paternal age. The most common error is maternal nondisjunction in the first meiotic division, with meiosis I errors occurring 3 times as frequently as meiosis II errors. The remaining cases are paternal in origin, and meiosis II errors predominate.
Advanced maternal age remains the only well-documented risk factor for maternal meiotic nondisjunction. However, understanding of the basic mechanism behind the maternal age effect is lacking. Maternal age risk factors are as follows:
- With a maternal age of 35 years, the risk is 1 in 385
- With a maternal age of 40 years, the risk is 1 in 106
- With a maternal age of 45 years, the risk is 1 in 30
Translocation occurs when genetic material from chromosome 21 becomes attached to another chromosome, resulting in 46 chromosomes with 1 chromosome having extra material from chromosome 21 attached. It may occur de novo or be transmitted by one of the parents. Translocations are usually of the centric fusion type. They frequently involve chromosome 14 (14/21 translocation), chromosome 21 (21/21 translocation), or chromosome 22 (22/21 translocation).
Mosaicism is considered a postzygotic event (ie, one that occurs after fertilization). Most cases result from a trisomic zygote with mitotic loss of one chromosome. As a result, 2 cell lines are found: one with a free trisomy, and the other with a normal karyotype. This finding leads to great phenotypic variability, ranging from near normal to the classic trisomy 21 phenotype.
Cytogenetic and molecular studies suggest that dup21(q22.1-22.2) is sufficient to cause Down syndrome. The DSCR contains genes that code for enzymes, such as superoxide dismutase 1 (SOD1), cystathionine beta-synthase (CBS), glycinamide ribonucleotide synthase-aminoimidazole ribonucleotide synthase-glycinamide formyl transferase (GARS-AIRS-GART).
Epidemiology
Down syndrome is the most common autosomal abnormality. The frequency is about 1 case in 800 live births. Each year, approximately 6000 children are born with Down syndrome.[12] Down syndrome accounts for about one third of all moderate and severe mental handicaps in school-aged children.
Age-related demographics
Down syndrome can be diagnosed prenatally with amniocentesis, percutaneous umbilical blood sampling (PUBS), chorionic villus sampling (CVS), and extraction of fetal cells from the maternal circulation. It is often diagnosed shortly after birth by recognizing dysmorphic features and the distinctive phenotype. The characteristic morphologic features will be obvious in children older than 1 year. Some dermatologic features increase with advancing age.
Occurrence is strongly dependent on maternal age. The incidence of this syndrome at various maternal ages is as follows:
- 15-29 years - 1 case in 1500 live births
- 30-34 years - 1 case in 800 live births
- 35-39 years - 1 case in 270 live births
- 40-44 years - 1 case in 100 live births
- Older than 45 years - 1 case in 50 live births
On rare occasions, the disease can be observed in a few members of a family. The risk for recurrence of Down syndrome in a patient’s siblings also depends on maternal age.
Sex-related demographics
Overall, the 2 sexes are affected roughly equally. The male-to-female ratio is slightly higher (approximately 1.15:1) in newborns with Down syndrome, but this effect is restricted to neonates with free trisomy 21.
Female patients with trisomy 21 have a 50% chance of having a child who also has the syndrome. However, many affected fetuses abort spontaneously. On the other hand, men with Down syndrome may be infertile, except for those with mosaicism.
Race-related demographics
Down syndrome has been reported in people of all races; no racial predilection is known. African American patients with Down syndrome have substantially shorter life spans than white patients with trisomy 21.
Prognosis
The overall outlook for individuals with Down syndrome has dramatically improved. Many adult patients are healthier, are better integrated into society, and have increased longevity than before. However, their life expectancy is still reduced.
Approximately 75% of concepti with trisomy 21 die in embryonic or fetal life. Approximately 25-30% of patients with Down syndrome die during the first year of life. The most frequent causes of death are respiratory infections (bronchopneumonia) and congenital heart disease. The median age at death is 49 years. However, some patients many reach their sixth decade.
Congenital heart disease is the major cause of morbidity and early mortality in patients with Down syndrome. In addition, esophageal atresia with or without transesophageal (TE) fistula, Hirschsprung disease, duodenal atresia, and leukemia contribute to mortality. The high mortality later in life may be the result of premature aging.
In elderly persons with Down syndrome, relative preservation of cognitive and functional ability is associated with better survival.[13] Clinically, the most important disorders related to mortality in this population are dementia, mobility restrictions, visual impairment, and epilepsy (but not cardiovascular disease). In addition, the level of intellectual disability and institutionalization are associated with mortality.
Individuals with Down syndrome have a greatly increased morbidity, primarily because of infections involving impaired immune response. Large tonsils and adenoids, lingual tonsils, choanal stenosis, or glossoptosis can obstruct the upper airway. Airway obstruction can cause serous otitis media, alveolar hypoventilation, arterial hypoxemia, cerebral hypoxia, and pulmonary arterial hypertension with resulting cor pulmonale and heart failure.
Leukemia, thyroid diseases, autoimmune disorders, epilepsy, intestinal obstruction, and increased susceptibility to infections (including recurrent respiratory infections) are commonly associated with Down syndrome.
The aging process seems to be accelerated in patients with Down syndrome. Many patients develop progressive Alzheimer-like dementia by age 40 years, and 75% of patients have signs and symptoms of Alzheimer disease.
A delay in recognizing atlantoaxial and atlanto-occipital instability may result in irreversible spinal-cord damage. Visual and hearing impairments in addition to mental retardation may further limit the child’s overall function and may prevent him or her from participating in important learning processes and developing appropriate language and interpersonal skills. Unrecognized thyroid dysfunction may further compromise central nervous system (CNS) function.
Patient Education
Career preparation should include acquisition of job skills, choice of job area, development of work-support behavior, and opportunities for job mobility. The goal of successful transition from school to the world of work is meaningful employment and optimal function in the least restrictive environment.
Opportunities to participate in community life should be made available. Individuals should be encouraged to pursue daily living tasks with minimal or no assistance. They should participate in cultural, leisure, and recreational activities during the growing years. Patients may qualify for supplemental security income (SSI) depending on their family’s income.
A parent’s guide to the genetics of Down syndrome is available.[7] Additional resources can be obtained from the following organizations:
- National Down Syndrome Society, 666 Broadway, 8th floor, New York, NY 10012-2317; 212-460-9330; fax, 212-979-2873; info@ndss.org
- National Down Syndrome Congress, 1370 Center Drive, Suite 102, Atlanta, GA 30338; 770-604-9500; info@ndscenter.org
- National Association for Down Syndrome, PO Box 206, Wilmette, IL 60091; 630-325-9112
- International Resource Center for Down Syndrome, Cleveland, OH
- The Arc, 1010 Wayne Avenue, Suite 650, Silver Spring, MD 20910; 301-565-3842
- The Down Syndrome Web site
For patient education resources, see the Brain and Nervous System Center, as well as Down Syndrome.
Lejeune J. Le mongolisme. Premier example d'aberration autosomique humaine. Ann Genet. 1959;1:41-9.
Jacobs PA, Baikie AG, Court Brown WM, Strong JA. The somatic chromosomes in mongolism. Lancet. Apr 4 1959;1(7075):710. [Medline].
Peterson MB, Mikkelsen M. Nondisjunction in trisomy 21: origin and mechanisms. Cytogenet Cell Genet. 2000;91:199-203.
Down JL. Observations on an ethnic classification of idiots. 1866. Ment Retard. Feb 1995;33(1):54-6. [Medline].
LEJEUNE J, GAUTIER M, TURPIN R. [Study of somatic chromosomes from 9 mongoloid children]. C R Hebd Seances Acad Sci. Mar 16 1959;248(11):1721-2. [Medline].
Levenson D. Talking about Down syndrome. Am J Med Genet A. Feb 15 2009;149A(4):vii-viii. [Medline].
[Guideline] Hartway S. A parent's guide to the genetics of Down syndrome. Adv Neonatal Care. Feb 2009;9(1):27-30. [Medline].
Ranweiler R. Assessment and care of the newborn with Down syndrome. Adv Neonatal Care. Feb 2009;9(1):17-24; Quiz 25-6. [Medline].
Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet. Feb 2001;17(2):83-8. [Medline].
Cheon MS, Shim KS, Kim SH, Hara A, Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part IV). Amino Acids. Jul 2003;25(1):41-7. [Medline].
[Guideline] American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities. National Guideline Clearinghouse. Jan 2007:[Full Text].
Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. Nov 2006;76(11):747-56. [Medline].
Coppus AM, Evenhuis HM, Verberne GJ, et al. Survival in elderly persons with Down syndrome. J Am Geriatr Soc. Dec 2008;56(12):2311-6. [Medline].
[Guideline] Cohen WI, ed. Health care guidelines for individuals with Down syndrome (Down syndrome preventative medical check list). Down Syndrome Q. 1996;1(2):1-10. [Full Text].
Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: Problems and possible solutions. Res Dev Disabil. 2009;30(5):827-838.
Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. May 2009;156(2):189-93. [Medline]. [Full Text].
Vis JC, Duffels MG, Winter MM, Weijerman ME, Cobben JM, Huisman SA. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res. May 2009;53(5):419-25. [Medline].
Lanfranchi S, Carretti B, Spanò G, Cornoldi C. A specific deficit in visuospatial simultaneous working memory in Down syndrome. J Intellect Disabil Res. May 2009;53(5):474-83. [Medline].
Levorato MC, Roch M, Beltrame R. Text comprehension in Down syndrome: the role of lower and higher level abilities. Clin Linguist Phon. Apr 2009;23(4):285-300. [Medline].
Salomon LJ, Bernard M, Amarsy R, Bernard JP, Ville Y. The impact of crown-rump length measurement error on combined Down syndrome screening: a simulation study. Ultrasound Obstet Gynecol. May 2009;33(5):506-11. [Medline].
Scherbenske JM, Benson PM, Rotchford JP, James WD. Cutaneous and ocular manifestations of Down syndrome. J Am Acad Dermatol. May 1990;22(5 Pt 2):933-8. [Medline].
Wilms A, Dummer R. [Elastosis perforans serpiginosa in Down syndrome]. Hautarzt. Dec 1997;48(12):923-5. [Medline].
Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. May-Jun 2007;24(3):317-20. [Medline].
Masjkey D, Bhattacharya S, Dhungel S, Jha CB, Shrestha S, Ghimire SR, et al. Utility of phenotypic dermal indices in the detection of Down syndrome patients. Nepal Med Coll J. Dec 2007;9(4):217-21. [Medline].
Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto's thyroiditis in Down's syndrome: clinical presentation and evolution. Horm Res. 2008;70(5):278-84. [Medline].
Shalitin S, Phillip M. Autoimmune thyroiditis in infants with Down's syndrome. J Pediatr Endocrinol. 2002;15:649-652.
Idris I, O'Malley BP. Thyrotoxicosis in Down's and Turner's syndromes: the likelihood of Hashimoto's thyroiditis as the underlying aetiology. Int J Clin Pract. 2000;54:272-273.
Rudberg C, Johansson H, Akerstrom G, Tuvema T, Karlsson FA. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol. 1996;134:710-7.
Zwaan MC, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in childrenwith Down syndrome. Pediatr Clin N Am. 2008;55:53-70.
Lerner LH, Wiss K, Gellis S, Barnhill R. An unusual pustular eruption in an infant with Down syndrome and a congenital leukemoid reaction. J Am Acad Dermatol. Aug 1996;35(2 Pt 2):330-3. [Medline].
Krivit W, Good RA. The simultaneous occurrence of leukemia and mongolism; report offour cases. AMA J Dis Child. 1956;91:218-222.
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. Jan 15 2000;355(9199):165-9. [Medline].
Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. Jan 2005;5(1):11-20. [Medline].
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. Jun 2005;37(6):613-9. [Medline].
Bhatt S, Schreck R, Graham JM, Korenberg JR, Hurvitz CG, Fischel-Ghodsian N. Transient leukemia with trisomy 21: description of a case and review of the literature. Am J Med Genet. Sep 25 1995;58(4):310-4. [Medline].
Roderick JA, Bradshaw WT. Transient myeloproliferative disorder in a newborn with Down syndrome. Adv neonat Care. 2008;8:208-218.
Gamis A, Hilden J. Transient myleoproliferative disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hemataopoiesis and acute myelogenous leukemia?. J Pediatr Hematol Oncol. 2002;24:2-5.
Ma SK, Wan TS, Chan GC, Ha SY, Fung LF, Chan LC. Relationship between transient abnormal myelopoiesis and acute megakaryoblastic leukaemia in Down's syndrome. Br J Haematol. Mar 2001;112(3):824-5. [Medline].
Magalhaes IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. Jan 2005;27(1):50-2. [Medline].
Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA-1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
Taub J. Down syndrome and megakaryocytic leukemia/transient myeloproliferative disorder: when does it begin?. Blood. 2003;101:4228-4300.
Al Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseasesin transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13.
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. Jun 15 2006;107(12):4606-13. [Medline].
Ringman JM, Rao N, Lu PH, Cederbaum S. Mosaicism for trisomy 21 in a patient with young-onset dementia. A case report and brief literature review. Arch Neurol. 2008;65:412-415.
Papavassiliou P, York TP, Gursoy N, Hill G, Nicely LV, Sundaram U. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A. Feb 15 2009;149A(4):573-83. [Medline].
Baum RA, Nash PL, Foster JE, Spader M, Ratliff-Schaub K, Coury DL. Primary care of children and adolescents with down syndrome: an update. Curr Probl Pediatr Adolesc Health Care. Sep 2008;38(8):241-61. [Medline].
Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. Feb 2009;14(2):164-73. [Medline].
Mik G, Gholve PA, Scher DM, Widmann RF, Green DW. Down syndrome: orthopedic issues. Curr Opin Pediatr. Feb 2008;20(1):30-6. [Medline].
Rogers PT, Roizen NJ, Capone GT. Down syndrome. In: Capute AJ, Accardo PJ. Developmental disabilities in infancy and childhood. 2nd. 1996:221-224.
Pueschel SM, Scola FH. Atlantoaxial instability in individuals with Down Syndrome: epidemiologic, radiographic, and clinical studies. Pediatrics. 1987;80:555-560.
Myers BA, Pueschel SM. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis. Oct 1991;179(10):609-13. [Medline].
Rice C. Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States,2002. MMWR CDC Surveill Summ. 2007;56:12-28.
Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol. Apr 2009;200(4):459.e1-9. [Medline].
Summerfield P. Prenatal screening for Down's syndrome: balanced debate needed. Lancet. Feb 28 2009;373(9665):722. [Medline].
Fransen MP, Hajo Wildschut, Vogel I, Mackenbach J, Steegers E, Essink-Bot ML. Information about prenatal screening for Down syndrome: ethnic differences in knowledge. Patient Educ Couns. Nov 2009;77(2):279-88. [Medline].
Dreux S, Olivier C, Dupont JM, Leporrier N, Oury JF. Maternal serum screening in cases of mosaic and translocation Down syndrome. Prenat Diagn. Aug 2008;28(8):699-703. [Medline].
Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol. Sep 2000;92(1):97-101. [Medline].
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. Aug 1 1998;352(9125):343-6. [Medline].
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. Mar 2005;25(3):221-6. [Medline].
Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. Jan 11 2011;342:c7401. [Medline]. [Full Text].
Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. Nov 2011;13(11):913-920. [Medline].
Warburton D, Dallaire L, Thangavelu M, Ross L, Levin B, Kline J. Trisomy recurrence: a reconsideration based on North American data. Am J Hum Genet. Sep 2004;75(3):376-85. [Medline].
Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson genetics in medicine. 6th Revised Reprint Edition. Philadelphia: W.B. Saunders; 2004.
Tolmie J. Down syndrome and other autosomal trisomies. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR. Emery and Rimoin's Principles and Practice of Medical Genetics. 4th edition. 2002:1129-1183.
Liyanage S, Barnes J. The eye and Down's syndrome. Br J Hosp Med (Lond). Nov 2008;69(11):632-4. [Medline].
Chen H, Woolley PV Jr. A developmental assessment chart for non-institutionalized Down syndrome children. Growth. Jun 1978;42(2):157-65. [Medline].
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. Jun 2008;31(6):618-24. [Medline].
Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. Jul 2004;191(1):45-67. [Medline].
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. Apr 1999;13(4):231-7. [Medline].

